Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

19.0%

4 terminated out of 21 trials

Success Rate

78.9%

-7.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed with results

Key Signals

5 with results79% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (5)
Early P 1 (1)
P 1 (9)
P 2 (5)

Trial Status

Completed15
Terminated4
Withdrawn2

Trial Success Rate

78.9%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT02122185Phase 2Completed

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00436254Phase 1Completed

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

NCT02013492Early Phase 1Completed

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

NCT01037790Phase 2Completed

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

NCT01322802Phase 1Completed

Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

NCT01846520Not ApplicableCompleted

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT01126346Not ApplicableCompleted

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT01080521Completed

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

NCT01494012Phase 1Terminated

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

NCT00957905Phase 2Completed

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT01155258Phase 1Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT01808534Phase 2Terminated

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01927393Not ApplicableWithdrawn

Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer

NCT01131234Phase 1Completed

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

NCT00228358Phase 1Completed

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

NCT00408655Phase 1Completed

Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT01233505Phase 1Terminated

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT01079832Phase 2Completed

Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

NCT00031681Phase 1Completed

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

NCT00087191Not ApplicableTerminated

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Scroll to load more

Research Network

Activity Timeline